Equivalence of a single saline nebulised dose of formoterol powder vs three doses of nebulised Albuterol every twenty minutes in acute asthma in children: A suitable cost effective approach for developing nations

Allergologia et Immunopathologia

Volumn 36, Issue 4, 2008, Pages 196-200

  Rodriguez, E ^a   Vera, V ^a   Perez Puigbo, A ^b   Capriles Hulett, A ^c   Ferro, S ^b   Manrique, J ^a   Abate, J ^d  

^a Elias Toro Children's Hospital   (Venezuela)

^b Hospital de Clinicas Caracas   (Venezuela)

^c Centro Medico Docente La Trinidad   (Venezuela)

^d Research and Data Processing Inc   (Venezuela)

Author keywords

Asthma; Children; Cost effectiveness; Developing countries; Formoterol; Salbutamol

Indexed keywords

ANTIASTHMATIC AGENT; FORMOTEROL FUMARATE; SALBUTAMOL;

ACUTE DISEASE; ARTICLE; ASTHMA; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG COST; HUMAN; LUNG FUNCTION; MEDICAL NEBULIZER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 55049136506     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1157/13127042     Document Type: Article

References (19)

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2006. Available from: http://www.ginasthma.org
2. Capriles E, Do Campo A, Verde O, Pluchino S, Capriles Hulett A. Children's asthma in the third world: an approach. J Investig Allergol Clin Immunol. 2006;16(1):11-18.
3. Avila-Castanon L, Casas-Becerra B, Del Rio-Navarro BE, Velazquez-Armenta Y, Sierra-Monge JJ. Formoterol vs Albuterol administered via Tubuhaler® in emergency treatment of acute asthma in children. Allergol et Immunopathol. 2004;32(1):18-20.
4. Boonsawat W, Charoebratanakul S, Pothirat C, Swanyawisuth K, Seearamroongruang T, Bengtsson T, Brander R, Selroos O. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacers in patients with acute severe asthma. Respr Med. 2003;97(9):1067-74.
5. Najafizadeh K, Sohrab Pour H, Ghadyanee M, Shiehmorteza M, Jamali M, Majdzadeh S. A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma. Emerg Med J. 2007;24(5):317-21.
6. Lee-Wong M, Chou V, Ogawa Y. Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting. Ann Allergy Asthma Immunol. 2008;100:164-52.
7. Berger W. The use of Formoterol in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;97:24-33.
8. Bensch G, Berger W, Blokhin B, Socolovsky AL, Thomson MH, Till MD, Castellague J, Della Cioppa G. International Study Group on Foradil evaluation in Pediatric Asthma. One year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol. 2002;89:180-90.
9. Pérez Puigbó A, Capriles Hulett A, Verde O, Rodríguez G, Pérez Reggeti J. Una nueva forma de administración: Reporte preliminar, efecto broncodilatador inmediato de Formoterol en solución salina vía Nebulización. Abstract No. 13 XIII Congreso de la Sociedad Venezolana de Alergia, Asma e Inmunología. Caracas Junio de 2000.
10. Pérez Puigbó A, Capriles Behrens E, Giannoni Delgado L. Nebulized Saline Solution of Dry Powder Formoterol is Useful for Acute Bronchospasm. Arch Venez Farmacol Terap. 2001;20(2):128-30.
11. Pérez Puigbó A, Capriles A, Giannoni L, Verde O y Rodríguez G. Una nueva alternativa terapéutica en el manejo del asma aguda (reporte preliminar). Alergia, Asma e Inmunología vol II, No. 2, 2000. pp.73-6.
12. Rodriguez E, Vera V, Perez-Puigbo A, Capriles-Hulett A, Manrique J, Abate J, Ferro S. A descriptive non-inferiority comparative analysis of single dose nebulized Formoterol powder (Foradil 24 μg) in isotonic saline vs three doses of albuterol (2.5 mg ampules, GSK) every twenty minutes for children's acute asthma: a cost effective approach for developing nations. World Allergy Congress 2007, Abstract 130, Bangkok, Thailand.
13. FDA approves Dey L.P.'s Perforomist® (Formoterol Fumarate) inhalation solution for maintenance treatment of COPD. Available from: www.medicalnewstoday.com.Respiratory/AsthmaNews, article date: 12 May 2007, accessed December 2007.
14. Nelson HS, Zu Wallack R, Levine B, Kerwin EM, Denis-Mize K, Rinehart M. "Safety Profile of Formoterol Fumarate Delivered by Nebulization to COPD Patients" ATS meeting 2007;Abstract A11.
15. Gorelick MH, Stevens MW, Schultz T, Scribano PW. Difficulty in obtaining peak expiratory flow measurements in children with acute asthma. Pediatr Emerg Care. 2004;20(1):22-6.
16. Ribeiro de Andrade C, Duarte MC, Camargos P. Correlations between pulse oximetry and peak expiratory flow in acute asthma. Braz J Med Biol Res. 2007;40(4):485-90.
17. Cates C. Spacers and nebulisers for the delivery of beta agonist in non-life-threatening acute asthma. Respiratory Medicine. 2003;97:762-9.
18. Watson JP, Lewis RA. Is asthma treatment affordable in developing countries? Thorax. 1997;52:605-7.
19. Lipworth BJ. Airway subsenstivitiy with long-acting beta 2 agonists. Is there a cause for concern? Drug Safety. 1997;16:295-308.